MassMutual Private Wealth & Trust FSB Buys New Shares in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

MassMutual Private Wealth & Trust FSB acquired a new position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 28,100 shares of the company’s stock, valued at approximately $209,000. MassMutual Private Wealth & Trust FSB owned about 0.08% of Lifecore Biomedical at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LFCR. Marshall Wace LLP raised its holdings in Lifecore Biomedical by 87.3% during the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock worth $1,540,000 after acquiring an additional 139,887 shares in the last quarter. 272 Capital LP increased its position in shares of Lifecore Biomedical by 511.1% during the 3rd quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after purchasing an additional 120,002 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Lifecore Biomedical during the 2nd quarter worth approximately $327,000. Geode Capital Management LLC raised its stake in shares of Lifecore Biomedical by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after purchasing an additional 55,703 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Lifecore Biomedical by 2,640.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after buying an additional 52,414 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Lifecore Biomedical Stock Performance

NASDAQ LFCR opened at $6.43 on Thursday. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $8.90. The firm has a 50-day moving average of $7.05 and a 200-day moving average of $5.92. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The stock has a market cap of $238.10 million, a PE ratio of -11.48 and a beta of 0.98.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. On average, sell-side analysts anticipate that Lifecore Biomedical, Inc. will post -1 EPS for the current year.

Insider Activity at Lifecore Biomedical

In other Lifecore Biomedical news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was acquired at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the purchase, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at $3,212,775.58. This trade represents a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 28.21% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on LFCR shares. Craig Hallum boosted their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 22nd. Stephens restated an “equal weight” rating and set a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.